5.4  0.03 (0.56%)		03-06 15:59
Open: 5.235 High: 5.4 Volume: 12,011		Pre. Close: 5.37 Low: 5.235 Market Cap: 21(M)

Short term
Mid term
Targets	6-month :	7.15	1-year :	8.35
Resists	First :	6.12	Second :	7.15
Pivot price	5.43
Supports	First :	4.94	Second :	4.21
MAs	MA(5) :	5.62	MA(20) :	5.25
	MA(100) :	5.07	MA(250) :	4.07
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	71.7	D(3) :	76.5
RSI	RSI(14): 49.3
52-week	High :	8.35	Low :	2.2

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ LONA ] has closed above bottom band by 48.4%. Bollinger Bands are 3.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	5.41 - 5.43	5.43 - 5.45
Low:	5.17 - 5.2	5.2 - 5.23
Close:	5.35 - 5.4	5.4 - 5.44

LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Thu, 26 Feb 2026
Cantor Fitzgerald initiates Leona Bio stock with overweight rating By Investing.com - Investing.com Nigeria

Tue, 03 Feb 2026
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer - GlobeNewswire

Mon, 12 Jan 2026
Athira Pharma (ATHA) Options to Be Delisted on January 12th - GuruFocus

Fri, 09 Jan 2026
Athira Pharma rebrands as LeonaBio amid strategic pivot to cancer therapy - Investing.com

Fri, 09 Jan 2026
Athira Pharma roars into the new year with rebrand to LeonaBio - Fierce Pharma

Fri, 09 Jan 2026
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	9 (M)
Shares Float	3 (M)
Held by Insiders	9.6 (%)
Held by Institutions	160.3 (%)
Shares Short	34 (K)
Shares Short P.Month	7 (K)

EPS	-9.68
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	6.78
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-42.3 %
Return on Equity (ttm)	-89.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-4.11
Qtrly Earnings Growth	0 %
Operating Cash Flow	-52 (M)
Levered Free Cash Flow	-30 (M)

PE Ratio	-0.56
PEG Ratio	0
Price to Book value	0.79
Price to Sales	0
Price to Cash Flow	-0.97

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.